Immunoenzymatic Biosensors and Molecular Nose

All our original know-how obtained in GPCRs Expression during the development of the HTS FRIDA platform has allowed us a prestigious entry in a great scientific and technical innovative field as is Odorant Receptors. First described in 1991, this large family of molecules (approx. 300 in humans and 1,000 in dogs and rats) has been difficult to express in heterologous cells, until Canvax achieved stable high-level expression of odour GPCRs into heterologous cell lines in 2014, aiming to develop a Molecular Nose with important applications in the Pharmaceutical industry as a Biosensor for the detection of cancer and other diseases, in the fragance industry to establish a molecular brand of a perfume; and even in the identification of individuals by their smell. We are highly committed with this relevant and exciting challenge and totally sure that our expertise and exclusive know-how favours this line of development. Obtaining a Molecular Nose for diagnostic purposes is an addition to Canvax‘s innovative biosensors area.

According to Immunoenzymatic Biosensors, we are developing Multiplex assay methods compatible with a wide range of proteins. Although multiplex tests are available for molecules against which antibodies are highly specific (e.g. Interleukins), it couldn’t be extended to the entire market of molecules that are detected by monoplex immunoenzymatic methods. In this area we are focused in the development of better assay surfaces, methods to coat them with orientated antibodies and more sensitive systems already in development.

Some examples:

hOR51E2 - Canvax Biotech
hFPRRS1 - Canvax Biotech
hOR3A1 - Canvax Biotech
hOR1D2 - Canvax Biotech
mORM7 - Canvax Biotech
mOR41-1 - Canvax Biotech